ReviewOpen access journal of sports medicine2025
Cardiac Screening in Athletes: Current Status and Future Challenges.
Review in Open access journal of sports medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-participation screening (PPS) is a primary-prevention strategy used in competitive sports to identify athletes at risk for cardiac diseases that can present with malignant arrhythmias and sudden cardiac death (SCD). Although compelling evidence supports the ability of PPS to lower SCD rates among athletes, no universal protocol has been adopted. Over time, however, key elements have emerged as common denominators: medical history, physical examination, and a 12-lead electrocardiogram (ECG). Research on ECG interpretation continues to evolve in search of the most accurate criteria for detecting cardiac disease, yet significant challenges persist. A major difficulty is the overlap between physiological remodeling in well-trained hearts and early manifestations of cardiomyopathy. In addition, some subgroups (female athletes, master athletes, and pediatric athletes) remain underrepresented in current studies. To ensure broad and equitable implementation, PPS must be supported by public-health policies and recognized as cost-effective, with the expectation that early identification of at-risk individuals will ultimately reduce the burden of advanced treatments on healthcare systems. Achieving this goal requires improving the sensitivity and specificity of existing screening tools to minimize misdiagnosis and avoid unnecessary secondary investigations or unwarranted disqualification from competition. This review summarizes the current status of cardiac screening in athletes, highlights persistent challenges, and outlines future directions to enhance its effectiveness and long-term sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.